Screening for Hepatocellular Carcinoma: What Is Missing?

Neil J. Mehta,1 Aygul Dogan Celik,1,2 and Marion G. Peters1

While there are guidelines from all major liver societies for the screening and management of hepatocellular carcinoma (HCC), many issues remain surrounding the actual practice of screening. This review discusses how to diagnose and screen HCC and more importantly, how well we diagnose and screen for HCC. Improved survival and outcomes after HCC diagnosis depend upon accurate diagnosis of cirrhosis and the timeliness of screening. With all oral direct-acting antivirals now widely available for hepatitis C, there are increasing numbers of patients who may be cured but are still at risk of HCC. Some uncontrolled studies suggest that direct-acting antiviral therapy may even increase the risk of HCC. Before we discuss expansion of who should be screened, we need physicians to realize how poorly we screen those patients who are already recommended for screening by guidelines. (HEPATOLOGY COMMUNICATIONS 2017;1:18-22)

How big is the problem?

The last four decades has seen a rising incidence of hepatocellular carcinoma (HCC) in the United States from 1.5 per 100,000 persons to nearly 14 per 100,000 persons and a 5-year survival under 12%.1 While most of the increase is associated with aging of the baby-boomer population with hepatitis C, hepatitis B and nonalcoholic fatty liver disease also contribute. In a Markov model of 2.7 million persons infected with the hepatitis C virus (HCV) who are in primary care in the United States, it is estimated that 1.47 million will develop cirrhosis and 350,000 will develop liver cancer over their lifetime. The burden of HCC from HCV is estimated to peak at 12,000 per year by approximately 2030.2

Who should be screened

Surveillance is the process of providing a screening test at regular intervals to patients at risk for HCC. Surveillance is deemed cost-effective if the expected HCC risk exceeds 1.5% per year in patients with hepatitis C and 0.2% per year in patients with hepatitis B.3 All patients with cirrhosis should be screened. While it is possible to perform HCC risk stratification in these patients using clinical risk scores4,5 and genomic biomarkers,6 neither yet appear able to reliably identify those patients with cirrhosis who are at such a low risk of HCC development that screening is not warranted. In addition to screening all patients with cirrhosis, hepatitis B virus (HBV) Asian males ≥ 40 years, Asian females ≥ 50 years, and sub-Saharan Africans ≥ 20 years as well as HBV patients with a family history of HCC should be screened. The European Association for the Study of the Liver (EASL) recommends screening HCV patients with stage 3 fibrosis as well.7 One of the major problems in deciding who to screen is in identifying those patients who have cirrhosis.8 If patients are decompensated with ascites, jaundice, encephalopathy, splenomegaly, and muscle wasting, the diagnosis is relatively easy. However, in some patients with Child's A

Abbreviations: AFP, alpha-fetoprotein; ALT, alanine aminotransferase; BCLC, Barcelona Clinic Liver Cancer; CT, computed tomography; EASL, European Association for the Study of the Liver; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; MRI, magnetic resonance imaging; SVR, sustained virologic response; VHA, Veterans Health Administration.

Received October 17, 2016; accepted November 1, 2016.

Copyright © 2016 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

View this article online at wileyonlinelibrary.com.
DOI 10.1002/hep4.1014

Potential conflict of interest: Dr. Peters has received honoraria for advisory boards from Merck, Hoffmann La Roche, Johnson and Johnson, Gilead Sciences, Abbott, and honorarium from Genentech. Spouse works for Hoffmann La Roche.
cirrhosis, few signs may be noted, and many such patients have normal liver tests. With decreasing use of liver biopsy, noninvasive markers of fibrosis may miss many patients. Transient elastography can be used to stage fibrosis in a noninvasive manner by measuring shear wave velocity. This technique is not readily available throughout the United States at this time so patients with cirrhosis may not be appropriately diagnosed.

How to screen

Screening is recommended by all liver societies; 6-monthly ultrasounds are recommended by the EASL and American Association for the Study of Liver Disease(7,9) and ultrasound and alpha-fetoprotein (AFP) are recommended by the Asian Pacific Association for the Study of the Liver.(10) Screening every 6 months is recommended because the doubling time of HCC is estimated to be 4-6 months.(11) The only randomized controlled trial of screening versus no screening was in 18,816 hepatitis B patients in China.(12) Patients underwent AFP and ultrasound every 6 months; 58.2% were screened and 41.8% were not. There were 86 tumors in the screened patients and 67 tumors in the nonscreened patients. Only the screened patients had subclinical, small, or resectable HCC lesions (Table 1). Survival was markedly better in those who were screened versus those who were not (65.9% versus 31.2% at 1 year; 46.4% versus 0% at 5 years).

AFP is limited as a screening test because of both false positives and false negatives. A third (20%-40%) of patients with HCC have normal AFP, and 20%-30% of patients without HCC have abnormal AFP, especially in those with active inflammation and elevated alanine aminotransferase (ALT) from HCV(5) and HBV.(13) Analyzing nearly 12,000 HCV patients with cirrhosis in the Veterans Health Administration (VHA) system, an AFP-based algorithm was created that also included ALT, platelet count, and age to predict the development of HCC. The authors found that taken alone, a patient with an AFP of 120 ng/mL had an 11% probability of developing HCC within 6 months; however, if that same patient was known to have minimal liver inflammation (ALT 40), platelet count of 100, and be older (age 70), the probability of developing HCC within 6 months rose to 29%. While AFP is not a particularly sensitive screening test and should be considered alongside additional clinical factors, such as ALT, there is no doubt that the higher the AFP, the more likely the diagnosis is HCC. In addition, AFP can be used as a prognostic marker because it predicts overall mortality in HCC,(14) predicts prognosis after resection,(15) and predicts prognosis after liver transplantation.(16-19)

If a nodule > 1 cm is found on ultrasound, quadruple-phase computed tomography (CT) or magnetic resonance imaging (MRI) is recommended.(3) Quadruple-phase CT is used to differentiate HCC, which is usually supplied by the hepatic artery, from normal liver tissue, which is mainly supplied by the portal vein. HCC is characterized by arterial phase enhancement and portal venous washout at the time the majority of the liver is enhanced. If either the CT or MRI shows the typical characteristics of HCC, then patients should be managed as per regular guidelines (e.g., Barcelona Clinic Liver Cancer [BCLC] staging classification(20)), without biopsy diagnosis. Biopsy of the lesion is recommended only in selected cases if there is an atypical radiologic appearance; this is because there are concerns with liver biopsy. False negative biopsies are common in clinical practice and may lead to delays in both diagnosis and treatment. Tumor seeding along the biopsy tract occurs in 1%-5% of cases, but coaxial biopsy may decrease this rate.(22) Seeding may exclude the patient from consideration of curative treatments, such as resection or transplant. If radiologic appearance and biopsy results are nondiagnostic or if the lesion is <1 cm, short-term follow-up with ultrasound (or CT/MRI if patient is listed for a transplant) in 3-4 months is recommended to assess growth of the lesion.

ARTICLE INFORMATION:
From the 1Department of Medicine, University of California, San Francisco, CA; and 1,2Department of Infectious Diseases and Clinical Microbiology, Trakya University School of Medicine, Edirne, Turkey.

ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO:
Marion Peters, M.D.
Division of Gastroenterology, Box 0538
University of California, San Francisco
513 Parnassus Ave, Room S-357
San Francisco, CA 94143-0538
E-mail: marion.peters@ucsf.edu
Tel: +1-415-502-0318
Singal studied 446 patients with cirrhosis who were prospectively enrolled for 6-monthly ultrasound and AFP. They excluded the first 6 months to avoid lead-time bias. After a median of 3.5 years, 41 patients were identified with HCC, 73.2% of whom had early lesions (BCLC stage 0-B) with the same percentage within Milan criteria and 80.5% within University of California, San Francisco criteria. They found an annual HCC incidence of 2.8% and a cumulative incidence at 3 and 5 years of 5.7% and 9.1%, respectively. The sensitivity of AFP and ultrasound was 90%, which was greater than either alone. However, screening came at a cost: 36 patients with high AFP had normal MRI and CT and 34 patients had a lesion on ultrasound that was not identified from MRI or CT.

Another retrospective study compared 6-monthly and yearly ultrasounds versus no screening in 269 patients with cirrhosis and HCC (Table 1). Those HCC patients who had appropriate screening had smaller lesions (70% within Milan criteria) compared to 37% for those screened yearly and 7% who had no screening. In addition, 3-year survival was better in 6-monthly (39%) screening versus yearly (27%) or no screening (12%). Among 821 Italian HCC patients who were studied retrospectively, no difference was found between 6- and 12-monthly screening compared to no screening. However, a later prospective study from the same group confirmed the benefit of 6-monthly screening over 12-monthly screening in 649 Italian patients with cirrhosis. As shown in Table 1, in those patients with 6-monthly screening, 70% were within Milan criteria compared to 58% of those screened yearly being within Milan criteria \(P < 0.001\). Screening more frequently (3 versus 6 months) increased detection of small focal lesions but not of HCC. Systematic reviews and meta-analysis of surveillance studies in patients with cirrhosis showed that those who had routine screening usually had earlier stage HCC, were more likely to be candidates for curative treatment, and had better survival compared to unscreened patients.

How well do we screen?

Studies from Europe and the United States show that less than 30% of patients with cirrhosis receive screening. In one study of 904 patients with cirrhosis in a US safety net hospital, less than 2% had biannual ultrasounds, 13% had annual ultrasounds, and 67% had only one ultrasound in 3 years. Lower surveillance was noted in the uninsured patients and in African Americans. Surveillance was highest in those who had a yearly visit to a hepatologist, followed by a visit to a primary care doctor; both were better than no follow-up visit. Two large, recent, retrospective studies of patients in the VHA and with commercial insurance found that twice yearly ultrasound screening in patients with cirrhosis was performed 20%-30% of the time. In the VHA study, some of the strongest predictors of not receiving screening included fewer visits with a subspecialist (gastrointestinal/hepatology/infectious disease), increased distance from a patient’s home to the nearest VHA center, and a longer time between the date the ultrasound was ordered and the date it was requested to be performed.

Screening of HCV patients after cure

Treatment of hepatitis C markedly decreases the risk of HCC but does not eradicate it. To emphasize
this, a study of 33,000 VHA patients identified 10,827 patients who achieved sustained virologic response (SVR) with interferon-based therapies; of those who achieved SVR, 100 developed new HCC.\(^{(33)}\) The annual incidence rate of HCC in those with SVR was 0.33\% per year compared to 1.32\% per year in those without SVR. The predictors of developing HCC in this cohort were cirrhosis at SVR (odds ratio, 6.69; confidence interval, 4.3-10.4), age over 65 years (4.51; 2.0-10.4), age 55-64 years (2.04; 1.3-3.2), Hispanic race compared to Caucasians (2.3; 1.1-1.8), diabetes mellitus (1.8; 1.2-2.9), and alcohol (1.68; 1.08-2.6).

Thus, patients who have SVR or are cured of their hepatitis C are still at risk of developing HCC, need to be monitored, and should not be discharged from their doctor’s practice. Literature over the past year has noted HCC occurring or recurring after SVR in response to direct acting antivirals. Uncontrolled studies reported early recurrence within 6-12 months of SVR,\(^{(34,35)}\) but the Agence Nationale de Recherche sur le Sida reported no difference in HCC incidence in those treated with interferon-based therapies versus direct-acting antivirals.\(^{(36)}\) Whether all oral direct-acting antiviral therapy is associated with an increased risk of cancer is not clear, and further long-term randomized studies are required.

In summary, there is an increasing prevalence of HCC with the aging of patients with hepatitis C, the increase of nonalcoholic fatty liver disease, as well as hepatitis B. There is much discussion about screening patients without cirrhosis as these patients can develop HCC. However, this opinion piece highlights that the major problem worldwide is how poorly we appropriately screen and diagnose HCC in patients with cirrhosis. What is most important is to diagnose cirrhosis early so that screening can be initiated because patients with cirrhosis are those with the highest risk of HCC. The outcome of HCC is influenced by the failure to diagnose cirrhosis, the absence of surveillance, and the delay in follow-up and treatment. Screening appropriately leads to early diagnosis, which leads to better management options, a higher proportion of treatable lesions, and better outcomes, including survival.

REFERENCES

1) El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365:1118-1127.
2) Rein DB, Wittenhorn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis 2011;43:66-72.
3) Sherman M, Bruix J, Forayko M, Tran T; AASLD Practice Guidelines Committee. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. Hepatology 2012;56:793-796.
4) Flemming JA, Yang JD, Vittinghoff E, Kim WR, Terrault NA. Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADDRESS-HCC risk model. Cancer 2014;120:3485-3493.
5) El-Serag HB, Kanwal F, Davila JA, Kramer J, Richardson P. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology 2014;146:1249-1255.
6) King LY, Canasto-Chibucque C, Johnson KB, Yip S, Chen X, Kojima K, et al. A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gastroenterology 2015;148:1296-1302.
7) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-943.
8) Singal AG, Yopp AC, Gupta S, Skinner CS, Halm EA, Okolo E, et al. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res (Phila) 2012;5:1124-1130.
9) Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022.
10) Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016;10:1-98.
11) An C, Choi YA, Choi D, Paik YH, Ahn SH, Kim MJ, et al. Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease. Clin Mol Hepatol 2015;21:279-286.
12) Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417-422.
13) Lok AS, Lai CL. alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology 1989;9:110-115.
14) Tyson GL, Duan Z, Kramer JR, Davila JA, Richardson PA, El-Serag HB. Level of alpha-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011;9:989-994.
15) Lee YH, Hsu CY, Huang YH, Su CW, Lin HC, Hsia CY, et al. alpha-fetoprotein-to-total tumor volume ratio predicts postoperative tumor recurrence in hepatocellular carcinoma. J Gastrointest Surg 2013;17:730-738.
16) Sarkar M, Dodge JL, Roberts JP, Terrault N, Yao F, Mehta N. Increased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant. Ann Hepatol 2016;15:545-549.
17) Berry K, Ioannou GN. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma. Liver Transpl 2013;19:634-645.
18) Duvoix C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, et al. Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012;143:986-994.
19) Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl 2014;20:945-951.
20) Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-338.
21) Forner A, Vilana R, Ayuso C, Bianchi L, Solé M, Ayuso JR, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008;47:97-104.

22) Maturen KE, Nghiem HV, Marrero JA, Hussain HK, Higgins EG, Fox GA, et al. Lack of tumor seeding of hepatocellular carcinoma after percutaneous needle biopsy using coaxial cutting needle technique. AJR Am J Roentgenol 2006;187:1184-1187.

23) Singal AG, Conjeevaram HS, Volk ML, Fu S, Fontana RJ, Askari F, et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev 2012;21:793-799.

24) Stravitz RT, Heuman DM, Chand N, Sterling RK, Shiffman ML, Luketic VA, et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med 2008;121:119-126.

25) Trevisani F, De Notariis S, Rapaccini G, Farinati F, Benvegnu L, Zoli M, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002;97:734-744.

26) Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol 2010;53:291-297.

27) Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, Fontaine H, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011;54:1987-1997.

28) Kansagara D, Papak J, Pasha AS, O’Neil M, Freeman M, Relevo R, et al. Screening for hepatocellular carcinoma in chronic liver disease: a systematic review. Ann Intern Med 2014;161:261-269.

29) Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014;11:e1001624.

30) Singal AG, Li X, Tiro J, Kandunoori P, Adams-Huet B, Nehra MS, et al. Racial, social, and clinical determinants of hepatocellular carcinoma surveillance. Am J Med 2015;128:90.

31) Goldberg DS, Taddei TH, Serper M, Mehta R, Dieperink E, Aytaman A, et al. Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis. Hepatology 2016; doi: 10.1002/hep.28765. [Epub ahead of print]

32) Goldberg DS, Valderrama A, Kamalakar R, Sanogry SS, Babajanyan S, Lewis JD. Hepatocellular Carcinoma Surveillance Among Cirrhotic Patients With Commercial Health Insurance. J Clin Gastroenterol 2016;50:258-265.

33) El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in patients with hepatitis C virus infection. Hepatology 2016;64:130-137.

34) Reig M, Mariño Z, Perelló C, Íñarraiaegui M, Ribeiro A, Lens S, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016;65:719-726.

35) Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727-733.

36) ANRS collaborative study group on hepatocellular carcinoma. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol 2016;65:734-740.